Interinstitutional variation in the use of abciximab for percutaneous coronary intervention

Canadian Journal of Cardiology

Volumn 20, Issue 4, 2004, Pages 405-410

  Westerhout, Cynthia M ^a   Saunders, L Duncan ^a   Kaul, Padma ^a   Armstrong, Paul W ^a   Knudtson, Merril L ^b   Ghali, William A ^b,c,d   Hui, William ^d   Archer, Stephen ^d   Curtis, Michael ^d   Graham, Michelle M ^d   Koshal, Arvind ^d   Maitland, Andrew ^d   Mitchell, L Brent ^d   Tsuyuki, Ross ^d   Galbraith, Diane ^d   Norris, Colleen M ^d   Sutherland, Karen ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d NONE   (Canada)

Author keywords

Angioplasty; Platelet aggregation inhibitors; Registries

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CANADA; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REOPERATION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 2342581609     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-91.
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
3. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
4. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-35.
5. Velianou JL, Strauss BH, Kreatsoulas C, Pericak D, Natarajan MK. Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: In-hospital and six-month outcomes. Catheter Cardiovasc Interv 2000;51:138-44.
6. Lucore CL, Trask RV, Mishkel GJ, et al. Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital. Coron Artery Dis 2001;12:135-42.
7. Paradiso-Hardy FL, Dolman SL, Schampaert E, Cohen EA. Utilization of abciximab (ReoPro) in Canadian catheterization laboratories. Can J Hosp Pharm 1998;51:79. (Abst)
8. O'Donnell MJ, Meengs WL, Maxwell-Edwards A, et al. The clinical paradox of worse outcomes with adjunctive abciximab in the setting of percutaneous transluminal coronary interventions: A report from the Blue Cross/Blue Shield of Michigan Cardiovascular Consortium. Circulation 1999;100(18 Suppl I):I-732. (Abst)
9. Plucinski DA, Krusmark J, Obenchain R, Scheltema K, McCollan P. A naturalistic study of abciximab use in percutaneous intervention. Am J Cardiol 2000;86(8 Suppl 1):TCT-171. (Abst)
10. Weiss JP, Reinhart SP, Yamashita BD. Abciximab utilization, costs, and outcomes in patients undergoing percutaneous revascularization. Circulation 1999;100(Suppl 18):3867. (Abst)
11. Ghali WA, Knudtson ML, on behalf of the APPROACH investigators. Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. Can J Cardiol 2000;16:1225-30.
12. Norris CM, Ghali WA, Knudtson ML, Naylor CD, Saunders, LD. Dealing with missing data in observational health care outcome analyses. J Clin Epidemiol 2000;53:377-83.
13. Kaul P, Saunders LD, Ghali WA, et al, for the APPROACH Investigators. Predictors of adverse events within one-year following percutaneous coronary intervention. Can J Cardiol 62000;16(Suppl F):284. (Abst)
14. Iezzoni LI. Risk-adjustment for Measuring Health Outcomes. Ann Arbor. Health Administration Press, 1994.
15. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa, integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343:881-6.
16. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-84.
17. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999;99:1951-8.
18. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa, Inhibitor for Stenting. Lancet 1999;354:2019-24.
19. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.